Literature DB >> 22573047

Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women.

Antonia García-Martín, Rebeca Reyes-García, Manuel Muñoz-Torres.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22573047     DOI： 10.1007/s12020-012-9694-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  3 in total

1.  Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study.

Authors:  Lars Rejnmark; Peter Vestergaard; Christine Brot; Leif Mosekilde
Journal:  Calcif Tissue Int       Date:  2010-12-23       Impact factor: 4.333

2.  Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism.

Authors:  Ilkay Cakir; Kursad Unluhizarci; Fatih Tanriverdi; Gulsah Elbuken; Zuleyha Karaca; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2012-02-12       Impact factor: 3.633

Review 3.  Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  Shonni J Silverberg; E Michael Lewiecki; Leif Mosekilde; Munro Peacock; Mishaela R Rubin
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958
  3 in total
  19 in total

1.  Polymorphisms of the vitamin D receptor and their effect on bone mass density in patients with normocalcemic hyperparathyroidism.

Authors:  Jose Luis Perez Castrillón; Gonzalo Díaz-Soto; Olatz Izaola Jauregui; Enrique Romero; Daniel de Luis Román
Journal:  Endocrine       Date:  2015-04-21       Impact factor: 3.633

Review 2.  Hyperparathyroidism and Bone Health.

Authors:  Francisco Bandeira; Sara Cassibba
Journal:  Curr Rheumatol Rep       Date:  2015-07       Impact factor: 4.592

Review 3.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 4.  Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm.

Authors:  Joaquín Gómez-Ramírez; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2017-08-19       Impact factor: 3.445

5.  Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Authors:  Emma O Billington; Greg D Gamble; Ian R Reid
Journal:  Bonekey Rep       Date:  2016-12-07

6.  Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.

Authors:  R Cesareo; E Di Stasio; F Vescini; G Campagna; R Cianni; V Pasqualini; F Romitelli; F Grimaldi; S Manfrini; A Palermo
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

Review 7.  Current opinions on nephrolithiasis associated with primary hyperparathyroidism.

Authors:  Xiaoming Cong; Luming Shen; Xiaojian Gu
Journal:  Urolithiasis       Date:  2018-01-19       Impact factor: 3.436

8.  Classic Primary Hyperparathyroidism Versus Normocalcemic and Normohormonal Variants: Do They Really Differ?

Authors:  Andreas Kiriakopoulos; Athanasios Petralias; Dimitrios Linos
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

9.  Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Authors:  Emanuela Traini; Rocco Bellantone; Serena Elisa Tempera; Salvatore Russo; Carmela De Crea; Celestino Pio Lombardi; Marco Raffaelli
Journal:  Langenbecks Arch Surg       Date:  2018-03-14       Impact factor: 3.445

10.  Involvement of α-klotho, fibroblast growth factor-, vitamin-D- and calcium-sensing receptor in 53 patients with primary hyperparathyroidism.

Authors:  Joerg Latus; Renate Lehmann; Meike Roesel; Peter Fritz; Niko Braun; Christoph Ulmer; Wolfgang Steurer; Dagmar Biegger; German Ott; Juergen Dippon; M Dominik Alscher; Martin Kimmel
Journal:  Endocrine       Date:  2013-01-20       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.